---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060209"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:32:15.565901+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q3 2023: Lung diagnostic revenue up 34% YoY; net loss narrows 20%

## Summary
- Total revenue $13.5M (+21% YoY); lung diagnostics $12.3M (+34% YoY); Biopharma Services $1.2M (+79% YoY).
- Lung diagnostic test volume >10,400 (+60% YoY); gross margin improved to 76% from 67%.
- Net loss $10.9M (-20% YoY); Adjusted EBITDA loss $5.4M (-40% YoY).
- FY 2023 revenue guidance lowered to $50-52M due to Medicare Advantage backlog removal; core business unchanged.
- Cash $19.8M at Sep 30; additional $10M draw from Perceptive term loan and final $12.2M private placement expected in Q4.

## SEC filing metadata
- accession: 0000950170-23-060209
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017023060209/0000950170-23-060209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017023060209/bdsx-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060209
- JSON: https://secwatch.observer/filing/0000950170-23-060209.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060209.txt

## Key facts
- Earnings Releases
  BIODESIX INC reported third quarter ended September 30, 2023 results: revenue $13.5 million, net income $10.9 million. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: $13.5 million
  - Net income: $10.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue of $13.5 million, an increase of 21%, including COVID testing revenue in third quarter 2022, driven primarily by strong year-over-year growth in lung diagnostics, and a 37% year-over-year increase excluding COVID testing revenues from the prior year comparison;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000095017023060209/0000950170-23-060209-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.